愛施德(002416.SZ):優友互聯申請新三板掛牌並定向發行事項獲受理
格隆匯3月5日丨愛施德(002416.SZ)公佈,有關公司控股子公司深圳市優友互聯股份有限公司申請新三板掛牌並同時定向發行事項,近日優友互聯收到全國中小企業股份轉讓系統有限責任公司出具的《受理通知書》(GP2023030002)、《受理通知書》(JGA23030002),優友互聯報送的新三板掛牌同時定向發行以及股票交易方式確定的申請材料,經審查符合《非上市公眾公司信息披露內容與格式準則第2號——公開轉讓股票申請文件》與《全國中小企業股份轉讓系統股票交易方式確定及變更指引》的相關要求,現予受理。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.